Qingdao Haier Biomedical Co Ltd
Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, transport coolers, and RTMD products; and CO2 in… Read more
Qingdao Haier Biomedical Co Ltd (688139) - Net Assets
Latest net assets as of June 2025: CN¥4.56 Billion CNY
Based on the latest financial reports, Qingdao Haier Biomedical Co Ltd (688139) has net assets worth CN¥4.56 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.61 Billion) and total liabilities (CN¥1.05 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.56 Billion |
| % of Total Assets | 81.22% |
| Annual Growth Rate | 26.09% |
| 5-Year Change | 65.85% |
| 10-Year Change | N/A |
| Growth Volatility | 42.7 |
Qingdao Haier Biomedical Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Qingdao Haier Biomedical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Qingdao Haier Biomedical Co Ltd (2016–2024)
The table below shows the annual net assets of Qingdao Haier Biomedical Co Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.62 Billion | +4.01% |
| 2023-12-31 | CN¥4.44 Billion | +7.03% |
| 2022-12-31 | CN¥4.15 Billion | +14.00% |
| 2021-12-31 | CN¥3.64 Billion | +30.68% |
| 2020-12-31 | CN¥2.78 Billion | +13.24% |
| 2019-12-31 | CN¥2.46 Billion | +120.78% |
| 2018-12-31 | CN¥1.11 Billion | +81.17% |
| 2017-12-31 | CN¥614.76 Million | -14.95% |
| 2016-12-31 | CN¥722.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Qingdao Haier Biomedical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 528.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.06 Billion | 47.13% |
| Other Components | CN¥2.31 Billion | 52.87% |
| Total Equity | CN¥4.37 Billion | 100.00% |
Qingdao Haier Biomedical Co Ltd Competitors by Market Cap
The table below lists competitors of Qingdao Haier Biomedical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Is Yatirim Menkul Degerler AS
IS:ISMEN
|
$642.75 Million |
|
Banco do Estado do Rio Grande do Sul S.A
SA:BRSR3
|
$642.78 Million |
|
Xizi Clean Energy Equipment Manufacturing Co Ltd
SHE:002534
|
$642.79 Million |
|
Ningbo PIA Automation Holding Corp. A
SHG:688306
|
$643.00 Million |
|
Cobram Estate Olives Ltd
AU:CBO
|
$642.39 Million |
|
Vestjysk Bank A/S
CO:VJBA
|
$642.31 Million |
|
Jiangsu Tongguang Electronic Wire&Cable Co Ltd
SHE:300265
|
$642.26 Million |
|
HIAG Immobilien Holding AG
SW:HIAG
|
$642.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qingdao Haier Biomedical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,230,710,930 to 4,371,550,511, a change of 140,839,582 (3.3%).
- Net income of 366,632,797 contributed positively to equity growth.
- Dividend payments of 163,089,771 reduced retained earnings.
- Other factors decreased equity by 62,703,444.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥366.63 Million | +8.39% |
| Dividends Paid | CN¥163.09 Million | -3.73% |
| Other Changes | CN¥-62.70 Million | -1.43% |
| Total Change | CN¥- | 3.33% |
Book Value vs Market Value Analysis
This analysis compares Qingdao Haier Biomedical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.38x to 2.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥2.59 | CN¥32.00 | x |
| 2018-12-31 | CN¥4.67 | CN¥32.00 | x |
| 2019-12-31 | CN¥7.74 | CN¥32.00 | x |
| 2020-12-31 | CN¥8.75 | CN¥32.00 | x |
| 2021-12-31 | CN¥11.43 | CN¥32.00 | x |
| 2022-12-31 | CN¥12.65 | CN¥32.00 | x |
| 2023-12-31 | CN¥13.31 | CN¥32.00 | x |
| 2024-12-31 | CN¥13.75 | CN¥32.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qingdao Haier Biomedical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.39%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.05%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.32x
- Recent ROE (8.39%) is below the historical average (12.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 17.05% | 25.56% | 0.51x | 1.31x | CN¥50.93 Million |
| 2017 | 9.82% | 9.72% | 0.52x | 1.94x | CN¥-1.08 Million |
| 2018 | 10.27% | 13.54% | 0.38x | 2.01x | CN¥3.00 Million |
| 2019 | 7.42% | 17.98% | 0.33x | 1.24x | CN¥-63.28 Million |
| 2020 | 13.72% | 27.17% | 0.36x | 1.42x | CN¥103.37 Million |
| 2021 | 23.33% | 39.75% | 0.43x | 1.35x | CN¥482.76 Million |
| 2022 | 14.94% | 20.98% | 0.52x | 1.37x | CN¥198.73 Million |
| 2023 | 9.60% | 17.80% | 0.41x | 1.31x | CN¥-17.00 Million |
| 2024 | 8.39% | 16.05% | 0.39x | 1.32x | CN¥-70.52 Million |
Industry Comparison
This section compares Qingdao Haier Biomedical Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,121,810,098
- Average return on equity (ROE) among peers: 128.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qingdao Haier Biomedical Co Ltd (688139) | CN¥4.56 Billion | 17.05% | 0.23x | $642.59 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $1.03 Billion | 22.10% | 0.17x | $320.58 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $6.16 Billion | 12.22% | 0.29x | $2.80 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $405.66 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $21.45K | 1180.66% | 90.26x | $283.55 Million |
| Lepu Medical Tech Beijing (300003) | $7.03 Billion | 12.79% | 0.82x | $2.80 Billion |
| INKON Life Technology Co Ltd (300143) | $74.89 Million | 13.27% | 0.87x | $630.90 Million |
| Edan Instruments Inc (300206) | $152.19 Million | 30.16% | 0.31x | $509.86 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.29 Billion | -5.53% | 0.94x | $378.42 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $269.46 Million |
| Sinocare Inc (300298) | $946.01 Million | 17.47% | 0.11x | $952.60 Million |